MDM2 and plasma cell myeloma: Jones and his colleagues (Jones et al., 2012) have found that the E3 ubiquitin ligase HDM2 played crucial roles in the cross-resistance of the myeloma cell line NCI-H929 to bortezomib, doxorubicin, cisplatin, and Mel.